Abivax

Abivax Obefazimod Safety Data Clears Cancer Risk, Reshaping Ulcerative Colitis Market Dynamics

Abivax's obefazimod has cleared significant cancer risk concerns with new Phase 3 data released July 1, 2026, causing a near 40% share surge and an $800 million share sale. This strengthens obefazimod's position as a potential oral "best-in-disease" treatment for ulcerative colitis, offering a differentiated safety profile against biologics and other small molecules, critically impacting future market access and competitive dynamics.